Back to today’s briefing

Story perspectives

Regeneron to Acquire 23andMe Amid Privacy Concerns

6/13/2025

43 5

Summary

Story summary

Regeneron Pharmaceuticals is set to acquire 23andMe for $256 million, a move designed to boost drug research. However, the deal is under the microscope from 27 states, including Texas and Michigan, raising alarms about genetic data ownership and privacy rights. A consumer privacy ombudsman will monitor the transaction, addressing rising concerns over data protection.

History

Historical Context

The Health Insurance Portability and Accountability Act (HIPAA), enacted in 1996, set crucial standards for patient information protection. This legislation paved the way for companies like 23andMe, founded in 2006, and Regeneron Pharmaceuticals, established in 1988, to innovate in genetic data and drug development. As scrutiny over genetic data privacy intensifies, the balance between innovation and consumer rights remains a pressing issue.

1 of 2

Story summary

Regeneron Pharmaceuticals is set to acquire 23andMe for $256 million, a move designed to boost drug research. However, the deal is under the microscope from 27 states, including Texas and Michigan, raising alarms about genetic data ownership and privacy rights. A consumer privacy ombudsman will monitor the transaction, addressing rising concerns over data protection.

1 / 2